# M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

> **NCT03840902** · PHASE2 · TERMINATED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 153 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** M7824
- **DRUG:** Placebo
- **DRUG:** Durvalumab
- **DRUG:** Etoposide
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **RADIATION:** Intensity Modulated Radiation Therapy (IMRT)

## Key facts

- **NCT ID:** NCT03840902
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-16
- **Primary completion:** 2023-02-17
- **Final completion:** 2023-02-17
- **Target enrollment:** 153 (ACTUAL)
- **Why stopped:** Based on recommendations by an external Independent data Monitoring Committee (IDMC), Sponsor decided to discontinue this clinical study due to a low likelihood of achieving superiority in the efficacy endpoints versus standard of care.
- **Last updated:** 2024-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03840902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03840902, "M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03840902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*